J Biol Regul Homeost Agents. 2020 May-Jun;34(3):757-766. doi: 10.23812/20-250-E-56.


EDITORIAL


>>> Request Full Article

Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.

Promoter of the study: NUOVA F.I.O. (Italian Oxygen-Ozone Federation), Marini S1, Maggiorotti M2, Dardes N3, Bonetti M4, Martinelli M5, Re L6, Carinci F7, Tavera C8.

Author information

1 Dati & Ricerca S.r.l., Rome, Italy.
2 New FIO National Secretary, Rome, Italy.
3 Paideia Clinic, Rome, Italy.
4 New FIO.
5 Villa S. Pietro Hospital, Rome, Italy.
6 Medinat, Camerano, Ancona, Italy.
7 Dental Faculty, University of Ferrara, Ferrara, Italy.
8 Potenziativa Medical Center, Como, Italy.

Abstract

The aim of the multicentre study promoted by Nuova FIO is to evaluate the beneficial effects of the systemic Oxygen-Ozone (O2O3) therapy in patients suffering from SARS COV-2 disease in the early phases of the disease, before worsening, up to the need of tracheal intubation. The study is based on the rationale on that the systemic oxygen-ozone treatment could be effective, positively influencing the disease evolution and/or being able to mitigate the onset of the cytokine storm syndrome at least partially.

KEYWORDS:

COVID-19, SARS-COV-2, clinical study, oxygen-ozone, protocol

Publication type

  • Editorial

>>> Request Full Article

You may also like...